Aethlon medical enters into materials transfer agreement for santersus ag's nucleocapture and hemonucleocapture devices

Aethlon medical will perform pre-clinical studies to explore potential synergies with its first-in-class hemopurifier® blood filtration system san diego , feb. 21, 2024 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a materials transfer agreement (mta) with santersus ag, a zurich-london based, privately held therapeutic medical device company, for santersus' nucleocapture and hemonucleocapture devices. under the terms of the mta, santersus will supply aethlon with nucleocapture and hemonucleocapture devices, designed to remove neutrophil extracellular traps (nets), which are toxic to tissues and organs and are implicated in the pathophysiology of cancer, sepsis, autoimmune diseases, such as lupus, and ischemia reperfusion injury in organ transplantation.
AEMD Ratings Summary
AEMD Quant Ranking